LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Darrell Denslow: New National Sales Director at Lattice Biologics
People In The News

Darrell Denslow: New National Sales Director at Lattice Biologics

June 30, 2016 1 min read Premium comments

Advertisement

Darrell Denslow: New National Sales Director at Lattice Biologics
Darrell Denslow

Darrell Denslow will now be heading up sales for Scottsdale, Arizona-based Lattice Biologics Ltd. According to the June 15, 2016 company newsletter, Denslow “started his career as a Spinal Consultant with Synthes Spine where he was consecutively a top performer for six years all while earning his Masters of Business Administration degree. He then took a position as Area Sales Director of the West for Orthofix Spine, eventually building his own distributorship based in Scottsdale. He brings an extensive background of biologic and allograft technologies and medical sales success accumulated over 20 years.”

Denslow told OTW, “I joined Lattice Biologics because I have an immense amount of respect for Guy Cook, the CEO. I was fortunate enough to be a distributor for his previous company and he played a key role in my success. In this role, I plan to continue to support and grow the existing Lattice Biologics business throughout the United States. To do this, I will leverage the strong surgeon and distribution relationships I have developed over the past 20 years. We anticipate a 200% or more increase in sales over the next fiscal year. This massive growth will help to fund the development of our game changing and revolutionary new cancer treatment technology.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy